Actoxumab  (Synonyms: 阿克托舒单抗; Anti-C. difficile Toxin A Recombinant Antibody)

Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Actoxumab (10 mg/kg WT or N297Q mutant (N297Q) actoxumab-bezlotoxumab; 2 h plus 24 h) significantly inhibits cell rounding activity in Vero cells under 2 ng/mL TcdA treatment^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Actoxumab (0.1-10 mg/kg or 50 mg/kg; i.p.; single dose) shows protective effect in multiple murine models of clostridium difficile infection (CDI), including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice^[1].
Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

145.9 (kDa)

1245634-25-6

液体

Colorless to light yellow

阿克托舒单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Yang Z, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015 Feb;83(2):822-31.  [Content Brief]